The temperature-sensitive liposomes have been developed by Celsion, of Columbia, Maryland, USA, and work in conjunction with radio-frequency ablation hyperthermia.
Under an agreement between NIH and Celsion, an animal toxicity study will take place under the supervision of principal investigator Dr Bradford Wood.
Pre-clinical studies have already been undertaken and published by scientists at Duke University, North Carolina, USA.
|The temperature-sensitive liposomes work in conjunction with radio-frequency ablation hyperthermia.
Dr Augustine Cheung, chief scientific officer of Celsion, said, "Based on Duke's published results, I am hopeful that the outcome of the testing at NIH will generate a similar level of success in liver tumor control in patients."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com